[A] Trends in Harvey–Bradshaw index [HBI] among patients switching to subcutaneous infliximab. HBI was measured at baseline and at 3, 6, and 12 months [m] after switch. Repeated measures analysis of variance [ANOVA] with correction for multiple measures were used to analyse trends. Overall, 63 values were available for comparison across all time points. Bars represent estimated marginal means and error bars represent 95% confidence intervals. [B] Trends in simple clinical colitis activity index [SCCAI] among patients switching to subcutaneous infliximab. SCCAI was measured at baseline and at 3, 6 and 12 months [m] after switch. Repeated measures ANOVA with correction for multiple measures was used to analyse trends. Overall, 32 values were available for comparison across all time points. Bars represent estimated marginal means and error bars represent 95% confidence intervals. [C] Trends in C-reactive protein [CRP] among patients switching to subcutaneous infliximab. CRP was measured at baseline and at 3, 6, and 12 months [m] after switch. Repeated measures ANOVA with correction for multiple measures was used to analyse trends. Overall, 111 values were available for comparison across all time points. Bars represent estimated marginal means and error bars represent 95% confidence intervals. [D] Trends in faecal calprotectin [FC] among patients switching to subcutaneous infliximab. FC was measured at baseline and at 3, 6, and 12 months [m] after switch. Repeated measures ANOVA with correction for multiple measures was used to analyse trends. Overall, 53 values were available for comparison across all time points. Bars represent estimated marginal means and error bars represent 95% confidence intervals.